SFI
PRLD icon

Susquehanna Fundamental Investments’s Prelude Therapeutics PRLD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,900
Closed -$273K – 1661
2021
Q4 		$273K Buy
+21,900
New +$356K 0.01% 1144

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Susquehanna Fundamental Investments's PRLD Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 21,900 shares — an estimated $273K sold.

Susquehanna Fundamental Investments first reported a position in PRLD in Q4 2021 and held it in 1 quarter. The position peaked at $273K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • Susquehanna Fundamental Investments reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 21,900 Prelude Therapeutics shares in Q1 2022, an estimated $273K.
  • Susquehanna Fundamental Investments first reported a position in Prelude Therapeutics in Q4 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Prelude Therapeutics position peaked at $273K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.